Results 151 to 160 of about 107,280 (285)

Identification of Novel β-Lactam Derivatives as Proteasome Inhibitors for Antitumor Therapy. [PDF]

Arch Pharm (Weinheim)
Cao Y, Xu G, Gao L, Sun J, Zhang L, Tong Q, Kong L, Zhang J, Zhou Y, Liao L, Fu L, Xi J.   +11 more
europepmc   +1 more source

A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β

Advanced Science, EarlyView.
This study demonstrates that the expression of A20, a ubiquitin‐editing enzyme, is positively correlated with oxaliplatin sensitivity in colorectal cancer (CRC). Mechanistically, A20 enhances oxaliplatin sensitivity by inhibiting NF‐κB nuclear translocation through monoubiquitination of IKK‐β.
Fan Luo, Ting Yang, Jiaxin Cao, Qun Chen, Zhenhai Lu, Feiteng Lu, Chaozhuo Lin, Zengfei Xia, Yuanzhong Yang, Peng Li, Wenjuan Ma, Min Luo, Rongxin Zhang   +12 more
wiley   +1 more source

Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system. [PDF]

Front Pharmacol
Li S, Ling T, Liu Y, Li J.
europepmc   +1 more source

Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors. [PDF]

J Med Chem, 2023
Thomas MG, McGonagle K, Rowland P, Robinson DA, Dodd PG, Camino-Díaz I, Campbell L, Cantizani J, Castañeda P, Conn D, Craggs PD, Edwards D, Ferguson L, Fosberry A, Frame L, Goswami P, Hu X, Korczynska J, MacLean L, Martin J, Mutter N, Osuna-Cabello M, Paterson C, Peña I, Pinto EG, Pont C, Riley J, Shishikura Y, Simeons FRC, Stojanovski L, Thomas J, Wrobel K, Young RJ, Zmuda F, Zuccotto F, Read KD, Gilbert IH, Marco M, Miles TJ, Manzano P, De Rycker M.   +40 more
europepmc   +1 more source

PFOS Disrupts Oocyte Maturation and Early Embryonic Development via Ovarian FOXK1 O‐GlcNAcylation in Mice

Advanced Science, EarlyView.
Perfluorooctane sulfonate (PFOS) exposure disrupts oocyte maturation and early embryonic development. This study elucidates the mechanism by which enhanced O‐GlcNAcylation of FOXK1 underlies the PFOS‐induced reduction of progesterone levels in granulosa cells and the disturbance of follicular microenvironment.
Shuwen Han, Qin Yuan, Zhu Wu, Yaohui Fang, Hong Qian, Jiale Zhu, Yuchen Zhang, Ke Deng, Liangliang Su, Haibo Xu, Haotian Shu, Yiming Gong, Qiaoqiao Xu, Guizhen Du, Di Wu, Yun Fan, Chuncheng Lu   +16 more
wiley   +1 more source

Peripheral Neuropathy Associated With Proteasome Inhibitors and Immunomodulatory Drugs: A Pharmacovigilance Disproportionality Analysis Using VigiBase. [PDF]

Pharmacol Res Perspect
Braga LP, de Pádua CAM, da Costa IHF, de Miranda Drummond PL, de Souza PHC, Fonseca LB, Rodrigues MA, Malta JS, Reis AMM.   +8 more
europepmc   +1 more source

Development of Potent and Highly Selective Epoxyketone-Based Plasmodium Proteasome Inhibitors. [PDF]

Chemistry, 2023
Almaliti J, Fajtová P, Calla J, LaMonte GM, Feng M, Rocamora F, Ottilie S, Glukhov E, Boura E, Suhandynata RT, Momper JD, Gilson MK, Winzeler EA, Gerwick WH, O'Donoghue AJ.   +14 more
europepmc   +1 more source

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

Advanced Science, EarlyView.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei, Wuqiang Wen, Wenjun Zhang, Shujing Zhang, Ting Sun, Guiming Li, Jing Zhang, Shuang Qi, Jie Zhou, Bing Li, Yunshuo Zhao, Xiaotong Chen, Bowen Li, Yiying Xue, Wang Lu, Yanli Sun, Jingyao Wang, Hengyue Shan, Shengzhe Zhang, Yushan Huang, Yisa Chen, Wenchao Wang, Qingsong Liu, Wenchao Lu, Li Tan, Yi Ding, Jianfei Fu, Jun Long, Lei Zhang, Baobing Zhao, Aibin Liang, Baishan Jiang, Jing Yang   +32 more
wiley   +1 more source

Aza-peptide aldehydes and ketones: synthesis and evaluation as human 20S proteasome inhibitors. [PDF]

Future Med Chem
Corrigan TS, Border SE, Lotti Diaz LM, Kasper KQ, Noonchester AM, Amer R, Kucway KS, Fleisher M, Fernandez JP, Lovins AR, Serrano AK, Caffrey CR, O'Donoghue AJ, Benson DM, Hadad CM, Ekici ÖD.   +15 more
europepmc   +1 more source

The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells [PDF]

, 2007
Liu X, Ping Yue, Shuzhen Chen, Liping Hu, Sagar Lonial, Fadlo R. Khuri, Shi‐Yong Sun   +6 more
openalex   +1 more source